Recent data suggest that patients with PV and hypertension who are treated with angiotensin-converting enzyme (ACE) inhibitors may require less cytoreductive treatment to control hematocrit levels compared with those who are treated with other antihypertensive agents [27]. The gene discussed is ACE; the disease is hypertensive disorder.